Comparative Pharmacology
Head-to-head clinical analysis: PREVACID 24 HR versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID 24 HR versus PRILOSEC OTC.
PREVACID 24 HR vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
15 mg orally once daily for 14 days.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor